These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12668890)

  • 1. Inhibitors of the complement system currently in development for cardiovascular disease.
    Pugsley MK; Abramova M; Cole T; Yang X; Ammons WS
    Cardiovasc Toxicol; 2003; 3(1):43-70. PubMed ID: 12668890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiology and pathophysiology of complement: progress and trends.
    Morgan BP
    Crit Rev Clin Lab Sci; 1995; 32(3):265-98. PubMed ID: 7495498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic inhibition of the early phase of complement activation.
    Roos A; Ramwadhdoebé TH; Nauta AJ; Hack CE; Daha MR
    Immunobiology; 2002 Sep; 205(4-5):595-609. PubMed ID: 12396018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of complement and complement regulatory proteins in glomerulonephritis.
    Quigg RJ
    Springer Semin Immunopathol; 2003 May; 24(4):395-410. PubMed ID: 12778335
    [No Abstract]   [Full Text] [Related]  

  • 5. Complement activation and inhibition in myocardial ischemia and reperfusion injury.
    Homeister JW; Lucchesi BR
    Annu Rev Pharmacol Toxicol; 1994; 34():17-40. PubMed ID: 8042849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic inhibition of the complement system.
    Makrides SC
    Pharmacol Rev; 1998 Mar; 50(1):59-87. PubMed ID: 9549758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The possibilities and pitfalls for anti-complement therapies in inflammatory diseases.
    Mizuno M; Morgan BP
    Curr Drug Targets Inflamm Allergy; 2004 Mar; 3(1):87-96. PubMed ID: 15032645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting complement in therapy.
    Kirschfink M
    Immunol Rev; 2001 Apr; 180():177-89. PubMed ID: 11414360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of complement inhibitors in myocardial ischaemia.
    Lucchesi BR; Tanhehco EJ
    Expert Opin Investig Drugs; 2000 May; 9(5):975-91. PubMed ID: 11060721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel series of potent and selective small molecule inhibitors of the complement component C1s.
    Subasinghe NL; Ali F; Illig CR; Jonathan Rudolph M; Klein S; Khalil E; Soll RM; Bone RF; Spurlino JC; DesJarlais RL; Crysler CS; Cummings MD; Morris PE; Kilpatrick JM; Sudhakara Babu Y
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3043-7. PubMed ID: 15149641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological manipulation of the complement system in human diseases.
    Asghar SS
    Front Biosci; 1996 Mar; 1():e15-25. PubMed ID: 9159241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future use of complement inhibitors for the treatment of neurological diseases.
    McGeer EG; McGeer PL
    Drugs; 1998 Jun; 55(6):739-46. PubMed ID: 9617589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlling the complement system in inflammation.
    Kirschfink M
    Immunopharmacology; 1997 Dec; 38(1-2):51-62. PubMed ID: 9476114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological manipulation of complement system.
    Asghar SS
    Pharmacol Rev; 1984 Dec; 36(4):223-44. PubMed ID: 6395140
    [No Abstract]   [Full Text] [Related]  

  • 15. Complement and its implications in cardiac ischemia/reperfusion: strategies to inhibit complement.
    Monsinjon T; Richard V; Fontaine M
    Fundam Clin Pharmacol; 2001 Oct; 15(5):293-306. PubMed ID: 11903498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The complement system: an old story or target of new therapeutic approaches?].
    Heller A; Koch T
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2000 Apr; 35(4):207-13. PubMed ID: 10830072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities.
    Gasque P; Neal JW; Singhrao SK; McGreal EP; Dean YD; Van BJ; Morgan BP
    Mol Neurobiol; 2002 Feb; 25(1):1-17. PubMed ID: 11890454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus.
    Rother RP; Mojcik CF; McCroskery EW
    Lupus; 2004; 13(5):328-34. PubMed ID: 15230287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the complement system.
    Marsh JE; Pratt JR; Sacks SH
    Curr Opin Nephrol Hypertens; 1999 Sep; 8(5):557-62. PubMed ID: 10541217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of complement in physiology and pathology].
    Klaska I; Nowak JZ
    Postepy Hig Med Dosw (Online); 2007; 61():167-77. PubMed ID: 17410057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.